Publications by authors named "A Hensen"

Inno4Vac, a public-private partnership funded by the IMI2/EU/EFPIA Joint Undertaking (IMI2 JU), brings together academic institutions, SMEs, and pharmaceutical companies to accelerate and de-risk vaccine development. The project has made significant strides in the selection and production of challenge agents for influenza, respiratory syncytial virus (RSV), and toxigenic Clostridioides difficile for controlled human infection model studies (CHIMs). A regulatory workshop held on March 20, 2024, addressed the standardisation of clinical procedures, ethical considerations, endpoints, and data integrity, highlighting the ongoing initiatives related to these CHIMs.

View Article and Find Full Text PDF

Malaria vaccines consisting of metabolically active Plasmodium falciparum (Pf) sporozoites can offer improved protection compared with currently deployed subunit vaccines. In a previous study, we demonstrated the superior protective efficacy of a three-dose regimen of late-arresting genetically attenuated parasites administered by mosquito bite (GA2-MB) compared with early-arresting counterparts (GA1-MB) against a homologous controlled human malaria infection. Encouraged by these results, we explored the potency of a single GA2-MB immunization in a placebo-controlled randomized trial.

View Article and Find Full Text PDF
Article Synopsis
  • Clostridioides difficile (C. difficile) is a major cause of healthcare-related diarrhea, with issues like antibiotic resistance and high relapse rates complicating treatment.
  • *Faecal microbiota transplantation is a potential therapy but understanding the key factors for successful colonization resistance is necessary for its broader application.
  • *Experts highlighted the need for a Controlled Human Infection Model (CHIM) to safely study mild to moderate C. difficile infections, which could lead to new treatments and better insights into how the infection works.*
View Article and Find Full Text PDF

HFC-23 is a potent greenhouse gas, predominantly emitted as an undesired by-product during the synthesis and processing of HCFC-22 (ref. ). Previously, the Clean Development Mechanism and national efforts called for the implementation of abatement technology for reducing HFC-23 emissions.

View Article and Find Full Text PDF